Big Pharma
16 October 2025 The court rejected Novartis’s request for emergency measures against a Spanish importer after the pharma company failed to meet the test to enforce an injunction, the winning lawyers told LSIPR.
10 October 2025
9 October 2025
9 October 2025
Latest Features
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler.
More News
8 October 2025 A 2021 Supreme Court ruling changed how patent terms are calculated, forcing pharma companies to rethink their IP strategies. Juliana Neves of Licks explains the key changes, upcoming reforms, and how companies can protect their portfolios effectively.
7 October 2025 The pharma giant will share rights to new innovations with an AI-driven organoid platform designed to produce fully human antibodies in weeks.
6 October 2025 Can AI tools raise the bar for inventiveness? And when algorithms become as productive as living systems, will they make their own outputs unpatentable? Industry experts unpick AI drug discovery’s biggest issues.
2 October 2025 From stalled drug approvals to suspended patent investigations, US rightsholders face mounting uncertainty during the federal freeze.
1 October 2025 Research reveals an increase in global filings in 2024/2025, but concerns remain over the future of vaccine development in the US.
26 September 2025 Sweeping tariffs send shockwaves through the pharma sector, as experts warn of consumer detriment and supply chain risks.
25 September 2025 A new survey from LSIPR reveals that European patent practitioners are grappling with client budget constraints and fast-evolving technologies, with most expecting patenting challenges to increase over the next five years.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox